logo
HP Profit Outlook Falls Short on Tariffs Costs, Economy

HP Profit Outlook Falls Short on Tariffs Costs, Economy

Bloomberg28-05-2025
HP Inc. gave a profit outlook for the current quarter that fell short of expectations, and cut its annual earnings forecast, pointing toward a weaker economy and continuing costs from US tariffs on goods from China. The shares fell about 15% in extended trading.
Earnings, excluding some items, will be 68 cents to 80 cents a share in the period ending in July, the maker of computers and printers said Wednesday in a statement. Analysts, on average, estimated 91 cents. Fiscal second-quarter profit was 71 cents a share, compared with the average estimate of 81 cents. Profit was dented by 12 cents from the impact related to tariffs and HP's spending to move manufacturing out of China, said Chief Financial Officer Karen Parkhill.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

WNBA All-Star 2025: Players take court in warm-up shirts reading 'Pay Us What You Owe Us' amid CBA talks
WNBA All-Star 2025: Players take court in warm-up shirts reading 'Pay Us What You Owe Us' amid CBA talks

Yahoo

time32 minutes ago

  • Yahoo

WNBA All-Star 2025: Players take court in warm-up shirts reading 'Pay Us What You Owe Us' amid CBA talks

The WNBA's ongoing CBA negotiations became a subplot of the All-Star Game the second the players stepped onto the court. Each player, as well as Caitlin Clark looking on from the bench, wore a black shirt reading "Pay Us What You Owe Us." It was a clear message to the WNBA after a week of seemingly fruitless talks in Indiana ahead of the All-Star festivities. It's never a great sign for a league when ESPN is discussing its players' demands during the middle of its All-Star Game, but the matter was unavoidable for the broadcast thanks to the shirts and other messages from the players. The WNBA players opted out of the current CBA last October, setting an expiration date on Oct. 31. A work stoppage looms if the two sides can't come to an agreement before the start of next season. Many All-Stars were present at an in-person talk between league and union officials on Thursday. The result of that meeting was a statement from the players calling the league's current proposal unsustainable: "We've told the League and teams exactly why their proposal falls so short. This business is booming — media rights, ratings, revenue, team valuations, expansion fees, attendance, and ticket sales — are all up in historic fashion. But shortchanging the working women who make this business possible stalls growth. The only thing more unsustainable than the current system is pretending it can go on forever." WNBA commissioner Cathy Engelbert responded by painting the conversation as "very constructive" and saying she is "optimistic" a deal will get done. There are a number of issues for the two sides to iron out, from the freedom of players to participate in other domestic and international leagues during the offseason (which almost always pays more than the WNBA) to the longstanding dispute over travel accommodations. The biggest point of contention is, of course, the distribution of money in a league set to make a reported $200 million per year for its media rights and charging a $250 million entry fee from each of the three incoming expansion teams. The players have been open with their demands and unhappiness about the state of the talks during the All-Star break, while the WNBA has mostly refrained from speaking out in recent months. Saturday represented one more time in which the players are forcing the issue into the public sphere.

Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025

Yahoo

time36 minutes ago

  • Yahoo

Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025

Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen's product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future revenue and profit growth. The acquisition also brought in new growth opportunities, especially with Tepezza, the first FDA-approved treatment for thyroid eye disease. In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported revenue of $8.15 billion, which showed a 9.4% growth from the same period last year. The company reported strong global demand for its products in the first quarter. Management expressed confidence in its long-term growth outlook, citing continued success with new product launches and positive Phase 3 trial results for several treatments. Amgen Inc. (NASDAQ:AMGN)'s free cash flow for the quarter came in at $1.0 billion, up from $0.5 billion in the prior year period. Its operating cash flow was $1.4 billion, compared to $0.7 billion in the same period last year. The company also returned $1.3 billion to shareholders through dividends during the quarter. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.19%, as of July 17. The company has raised its payouts since the inception of its dividend policy in 2011. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?

Yahoo

time36 minutes ago

  • Yahoo

Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?

AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store